Published in Blood Weekly, July 31st, 2003
NaPro's technique for approaching sickle cell disease is to make the single base pair correction in hematopoietic stem/progenitor cells ex vivo and then reinfuse the patients with their own corrected cells.
"We are very excited to collaborate with NaPro. Their unique approach is an intriguing development in addressing this disease at the genetic level,"...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.